Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 2, 2007, Pages 348-356

  Jordan, Shaun ^a   Johnson, Janelle L ^a   Regardie, Karen ^a   Chen, Ruoyan ^a   Koprivica, Vuk ^a   Tadori, Yoshihiro ^b   Kambayashi, Junichi ^a   Kitagawa, Hisashi ^b   Kikuchi, Tetsuro ^b  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aripiprazole; Dopamine; In vitro binding assay; Partial agonist; Schizophrenia

Indexed keywords

7 [3 [4 (2,3 DIMETHYLPHENYL) 1 PIPERAZINYL]PROPOXY] 2(1H) QUINOLINONE; ADENOSINE PHOSPHATE; ARACHIDONIC ACID; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FORSKOLIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PARTIAL AGONIST; RACLOPRIDE; TERGURIDE; ZIPRASIDONE; CYCLIC AMP; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; SULFUR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CLONE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MEMBRANE BINDING; NONHUMAN; RAT; SIGNAL TRANSDUCTION; ANIMAL; BINDING COMPETITION; CELL CULTURE; CELL MEMBRANE; COMPARATIVE STUDY; CRICETULUS; CYTOLOGY; DOSE RESPONSE; GENETIC TRANSFECTION; HAMSTER; METABOLISM; METHODOLOGY; NERVE CELL; PHYSIOLOGY; PROTEIN BINDING; SPRAGUE DAWLEY RAT;

ANIMALS; ARACHIDONIC ACID; BINDING, COMPETITIVE; CELL MEMBRANE; CELLS, CULTURED; CORPUS STRIATUM; CRICETINAE; CRICETULUS; CYCLIC AMP; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MALE; NEURONS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION; SULFUR ISOTOPES; TRANSFECTION;

EID: 33846821695     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.09.007     Document Type: Article

References (47)

1. Akam E., and Strange P.G. Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol 67 (2004) 2039-2045
2. Benkert O., Muller-Siecheneder F., and Wetzel H. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol 5 Suppl (1995) 43-53
3. 35S]GTP gamma S binding. Methods Mol Biol 237 (2004) 135-143
4. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302 (2002) 381-389
5. Burstein E.S., Ma J., Wong S., Gao Y., Pham E., Knapp A.E., et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315 (2005) 1278-1287
6. Clark D., Hjorth S., and Carlsson A. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62 (1985) 1-52
7. Clark D., Hjorth S., and Carlsson A. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm 62 (1985) 171-207
8. Coldwell M.C., Boyfield I., Brown A.M., Stemp G., and Middlemiss D.N. Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127 (1999) 1135-1144
9. Fujikawa M., Nagashima M., Inoue T., Yamada K., and Furukawa T. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav 53 (1996) 903-909
10. Gardner B.R., Hall D.A., and Strange P.G. Agonist action at D2(short) dopamine receptors determined in ligand binding and functional assays. J Neurochem 69 (1997) 2589-2598
11. Hoyer D., and Boddeke H.W. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14 (1993) 270-275
12. Huff R.M. Signal transduction pathways modulated by the D2 subfamily of dopamine receptors. Cell Signal 8 (1996) 453-459
13. Inoue A., Miki S., Seto M., Kikuchi T., Morita S., Ueda H., et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 321 (1997) 105-111
14. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., and Altar C.A. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483 (2004) 45-53
15. Jordan S., Chen R., Johnson J., Regardie K., Tadori Y., and Kikuchi T. In vitro effects of antipsychotic drugs on second and third messengers of human dopamine D2 receptor signaling. Soc Neurosci Abstr 35 (2005) 913.912
16. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63 (2002) 763-771
17. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63 (2002) 763-771
18. Kanterman R.Y., Mahan L.C., Briley E.M., Monsma Jr. F.J., Sibley D.R., Axelrod J., et al. Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Mol Pharmacol 39 (1991) 364-369
19. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15 (2001) 598-611
20. Kenakin T. Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42 (2002) 349-379
21. Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274 (1995) 329-336
22. Koller W.C., and Herbster G. Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease. Neurology 37 (1987) 723-727
23. Lahti R.A., Figur L.M., Piercey M.F., Ruppel P.L., and Evans D.L. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol 42 (1992) 432-438
24. Lahti A.C., Weiler M.A., Corey P.K., Lahti R.A., Carlsson A., and Tamminga C.A. Antipsychotic properties of the partial dopamine agonist (-)-3-(3- hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 43 (1998) 2-11
25. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
26. Li G., and Qian H. Sensitivity and specificity amplification in signal transduction. Cell Biochem Biophys 39 (2003) 45-59
27. Lieberman J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18 (2004) 251-267
28. Lledo P.M., Homburger V., Bockaert J., and Vincent J.D. Differential G protein-mediated coupling of D2 dopamine receptors to K+ and Ca2+ currents in rat anterior pituitary cells. Neuron 8 (1992) 455-463
29. Meller E., Bohmaker K., Namba Y., Friedhoff A.J., and Goldstein M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 31 (1987) 592-598
30. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Dopamine receptors: from structure to function. Physiol Rev 78 (1998) 189-225
31. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10 (2005) 79-104
32. Neve K.A., Seamans J.K., and Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 24 (2004) 165-205
33. Nilsson C.L., and Eriksson E. Haloperidol increases prolactin release and cyclic AMP formation in vitro: inverse agonism at dopamine D2 receptors?. J Neural Transm Gen Sect 92 (1993) 213-220
34. Piomelli D., Pilon C., Giros B., Sokoloff P., Martres M.P., and Schwartz J.C. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 353 (1991) 164-167
35. Roberts D.J., and Strange P.G. Mechanisms of inverse agonist action at D2 dopamine receptors. Br J Pharmacol 145 (2005) 34-42
36. Roberts D.J., Lin H., and Strange P.G. Mechanisms of agonist action at D2 dopamine receptors. Mol Pharmacol 66 (2004) 1573-1579
37. Seabrook G.R., Knowles M., Brown N., Myers J., Sinclair H., Patel S., et al. Pharmacology of high-threshold calcium currents in GH4C1 pituitary cells and their regulation by activation of human D2 and D4 dopamine receptors. Br J Pharmacol 112 (1994) 728-734
38. Seeman P., Lee T., Chau-Wong M., and Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261 (1976) 717-719
39. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
40. Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T., et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 515 (2005) 10-19
41. Tamminga C.A. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109 (2002) 411-420
42. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has Functionally Selective Actions at Dopamine D(2) Receptor-Mediated Signaling Pathways. Neuropsychopharmacology; Advance on-line publication March 22, 2006.
43. Vallar L., and Meldolesi J. Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol Sci 10 (1989) 74-77
44. Vallar L., Muca C., Magni M., Albert P., Bunzow J., Meldolesi J., et al. Differential coupling of dopaminergic D2 receptors expressed in different cell types. Stimulation of phosphatidylinositol 4,5-bisphosphate hydrolysis in LtK-fibroblasts, hyperpolarization, and cytosolic-free Ca2+ concentration decrease in GH4C1 cells. J Biol Chem 265 (1990) 10320-10326
45. Vanhauwe J.F., Ercken M., van de Wiel D., Jurzak M., and Leysen J.E. Effects of recent and reference antipsychotic agents at human dopamine D2 and D3 receptor signaling in Chinese hamster ovary cells. Psychopharmacology (Berl) 150 (2000) 383-390
46. Yasuda Y., Kikuchi T., Suzuki S., Tsutsui M., Yamada K., and Hiyama T. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Life Sci 42 (1988) 1941-1954
47. 3H]dopamine. Eur J Pharmacol 155 (1988) 323-327